This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Bossola, M. Articles by Doglietto, G. B. Search for Related Content PubMed PubMed Citation Articles by Bossola, M. Articles by Doglietto, G. B.

Cancer Cachexia: It’s Time for More Clinical Trials

Istituto di Clinica Chirurgica, Università Cattolica del Sacro Cuore, Roma, Italia

Correspondence: Address correspondence and reprint requests to: Maurizio Bossola. Istituto di Clinica Chirurgica, Università Cattolica del Sacro Cuore, Largo A. Gemelli, 8, 00168, Roma, Italia; E-mail: maubosso{at}tin.it

Cancer cachexia (CC) is a multifactorial paraneoplastic syndrome characterized by anorexia, body weight loss, loss of adipose tissue and skeletal muscle, accounting for at least 20% of deaths in neoplastic patients. CC significantly impairs quality of life and response to anti-neoplastic therapies, increasing morbidity and mortality of cancer patients. Muscle wasting is the most important phenotypic feature of CC and the principal cause of function impairment, fatigue and respiratory complications, mainly related to a hyperactivation of muscle proteolytic pathways. Most current therapeutic strategies to counteract CC have proven to be only partially effective. In the last decade, the correction of anorexia, the inhibition of catabolic processes and the stimulation of anabolic pathways in muscle have been attempted pharmacologically with encouraging results in animal models and through preliminary clinical trials. However, data in the clinical setting are still scanty and non definitive. It is time to start prospective, randomized, controlled trials to evaluate which drugs are effective in counteracting the loss of lean of muscle mass and in improving nutritional status and quality of life in patients affected by cancer-related cachexia.

Key Words: Cancer cachexia • Anorexia • Muscle wasting • Approved therapy • Candidate drugs

This article has been cited by other articles:

				L. Genton and C. Pichard Do Obese Patients Have Specific Nutrition Goals in Cases of Cancer? JPEN J Parenter Enteral Nutr, July 1, 2009; 33(4): 442 - 443. [Full Text] [PDF]

				S. Al-Majid and H. Waters The biological mechanisms of cancer-related skeletal muscle wasting: the role of progressive resistance exercise. Biol Res Nurs, July 1, 2008; 10(1): 7 - 20. [Abstract] [PDF]